ASCOT Legacy: the first long-term monitoring of the effect of antihypertensive treatment combined with statin on mortality
Authors:
Michal Vrablík
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
AtheroRev 2020; 5(1): 43-45
Category:
clinical studies
Sources
- Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67185–1>.
- Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet 2018; 392(10153): 1127–1137. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31776–8>.
- Margolis KL, Davis BR, Baimbridge C et al. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens 2013; 15(8): 542–554. Dostupné z DOI: <http://dx.doi.org/10.1111/jch.12139>.
- Kostis WJ, Moreyra AE, Cheng JQ et al. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. J Clin Lipidol 2011; 5(2): 97–104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2011.01.006>.
- Ford I, Murray H, McCowan C et al. Long term safety and efficacy of lowering LDL-cholesterol with statin therapy: 20-year follow up of West of Scotland Coronary Prevention Study. Circulation 2016; 133(11): 1073–1080. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019014>.
- Hague WE, Simes J, Kirby A et al. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: 16 years of follow-up of the LIPID Study. Circulation 2016 : 133(19): 1851–1860. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018580>
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2020 Issue 1
- Hope Awakens with Early Diagnosis of Parkinson's Disease Based on Skin Odor
- Metamizole vs. Tramadol in Postoperative Analgesia
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Memantine Eases Daily Life for Patients and Caregivers
-
All articles in this issue
- Editorial
- Editorial
- Homocysteine consensus
- Comments on the new recommendations for dyslipidemia and cardiovascular risk management with regard to diabetes mellitus
- Hypercholesterolemia as a risk factor for hearing loss: Do we have sufficient evidence?
- Uric acid and influence of hyperuricaemia therapy on prevention of atheroscleroris and cardiovascular diseases
- Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents
- Pitfalls of diet therapy in dyslipidemias
- ASCOT Legacy: the first long-term monitoring of the effect of antihypertensive treatment combined with statin on mortality
- Characteristics of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in Czechia– LipitenCliDec Study: 1st phase results
- Horúce novinky zo štúdie ODYSSEY OUTCOMES (kongres American Heart Association november 2019)
- Rešerše zajímavých článků ze zahraniční literatury
- Zprávy z odborných akcí ČSAT
- Athero Review
- Journal archive
- Current issue
- About the journal
Most read in this issue
- Uric acid and influence of hyperuricaemia therapy on prevention of atheroscleroris and cardiovascular diseases
- Comments on the new recommendations for dyslipidemia and cardiovascular risk management with regard to diabetes mellitus
- Homocysteine consensus
- Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents